The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Sugammadex Mylan sugammadex Generic | Mylan Pharmaceuticals Limited | Neuromuscular Blockade | 🇪🇺 EU 2021-11-15 | Order → |
| Vumerity diroximel fumarate | Biogen Netherlands B.V. | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2021-11-15 | Order → |
| Libmyris adalimumab Biosimilar | Stada Arzneimittel AG | Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Psoriasis; Hidradenitis Suppurativa; Crohn Disease; Coliti | 🇪🇺 EU 2021-11-12 | Order → |
| Regkirona regdanvimab Additional monitoring | Celltrion Healthcare Hungary Kft. | COVID-19 virus infection | 🇪🇺 EU 2021-11-12 | Order → |
| Rivaroxaban Viatris (previously Rivaroxaban Mylan) rivaroxaban Generic | Viatris Limited | Venous Thromboembolism; Pulmonary Embolism; Acute Coronary Syndrome; Stroke; Coronary Artery Disease; Peripheral Arterial Disease; Atrial Fibrillation | 🇪🇺 EU 2021-11-12 | Order → |
| Ronapreve casirivimab;imdevimab Additional monitoring | Roche Registration GmbH | COVID-19 virus infection | 🇪🇺 EU 2021-11-12 | Order → |
| Imatinib Koanaa imatinib Generic | Koanaa Healthcare GmbH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Hypereosinophilic | 🇪🇺 EU 2021-09-22 | Order → |
| Ozawade pitolisant | Bioprojet Pharma | Sleep Apnea, Obstructive | 🇪🇺 EU 2021-09-01 | Order → |
| Minjuvi tafasitamab OrphanConditionalAdditional monitoring | Incyte Biosciences Distribution B.V. | Lymphoma, Large B-Cell, Diffuse | 🇪🇺 EU 2021-08-26 | Order → |
| Voxzogo vosoritide Orphan | BioMarin International Limited | Achondroplasia | 🇪🇺 EU 2021-08-26 | Order → |
| Abiraterone Mylan abiraterone acetate Generic | Mylan Pharmaceuticals Limited | Prostatic Neoplasms | 🇪🇺 EU 2021-08-20 | Order → |
| Bimzelx bimekizumab | UCB Pharma S.A. | Psoriasis | 🇪🇺 EU 2021-08-20 | Order → |
| Abecma idecabtagene vicleucel OrphanPRIMEATMP | Bristol-Myers Squibb Pharma EEIG | Multiple Myeloma | 🇪🇺 EU 2021-08-18 | Order → |
| Byooviz ranibizumab BiosimilarAdditional monitoring | Samsung Bioepis NL B.V. | Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Myopia, Degenerative | 🇪🇺 EU 2021-08-18 | Order → |
| Evrenzo roxadustat | Astellas Pharma Europe B.V. | Anemia; Kidney Failure, Chronic | 🇪🇺 EU 2021-08-18 | Order → |
| Fingolimod Mylan fingolimod Generic | Mylan Pharmaceuticals Limited | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2021-08-18 | Order → |
| Fingolimod Mylan fingolimod Generic | Mylan Ireland Limited | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2021-08-18 | Order → |
| Bylvay odevixibat OrphanPRIMEExceptional circumstances | Ipsen Pharma | Cholestasis, Intrahepatic | 🇪🇺 EU 2021-07-16 | Order → |
| Icatibant Accord icatibant Generic | Accord Healthcare S.L.U. | Angioedemas, Hereditary | 🇪🇺 EU 2021-07-16 | Order → |
| Imcivree setmelanotide OrphanPRIME | Rhythm Pharmaceuticals Netherlands B.V. | Obesity | 🇪🇺 EU 2021-07-16 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.